Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancer (ED SCLC) Source: International Congress 2019 – Treatment of lung cancer Year: 2019
Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011
Managing the initial treatment and multiple relapses in a small cell lung cancer patient with limited disease Source: International Congress 2018 – CC3 Lung cancer: personalised treatment and palliative care Year: 2018
Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009
The delays due to patient‘s and doctors‘ in non- small cell lung cancer patients Source: Annual Congress 2003 - Lung cancer management and prognosis Year: 2003
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019
Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care. Source: International Congress 2019 – Treatment of lung cancer Year: 2019
Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors Year: 2008
Reflex testing is crucial for treatment decisions in advanced non small cell lung cancer (NSCLC) Source: International Congress 2017 – Chinese Programme 2017 Year: 2017
Small cell lung cancer patients and their responses to treatment Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007
Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Challenges in the management of SCLC Part 2: Extensive disease, prophylaxis/treatment of brain metastases Source: ERS webinar 2021: Challenges in the management of SCLC Part 2: Extensive disease, prophylaxis/treatment of brain metastases Year: 2021
Small cell lung cancer in patients with elderly Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007
Clinical characteristics, treatment, and prognosis of lung cancer elderly patients Source: Eur Respir J 2001; 18: Suppl. 33, 228s Year: 2001
Rates of treatment response and median survival in advanced non small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Quality indicators in lung cancer care-review of resection rates in early stage NSCLC (non small cell lung cancer) at King’s Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement Year: 2018